Not actual healthcare provider
Healthcare Providers can now digitally submit a patient’s application and supporting documentation for the Dermavant RxAssist Program and get eligible patients started on VTAMA (tapinarof) cream, 1% in as little as 12-72 hours!*
Digital patient authorization Send your patients a secure link to provide them digital authorization at their convenience.
Real-time application submittal Digitally submit the patient’s application and supporting documentation in minutes.
Digital capture of patient and prescriber authorization facilitates timely access to patient support services.
Electronic submission reduces missing, incomplete or illegible information that could cause access delays.
Ability to upload patient medical history, tax documents, income statements and other supporting documentation streamlines the process.
Your patient’s annual household income does not exceed 250% of the Federal poverty level‡:
Apply today to help your patients gain access to VTAMA (tapinarof) cream, 1%.
Our support teams are available to help you Monday through Friday, 8 a.m. – 5 p.m. ET.
For Dermavant RxAssist Program:
IMPORTANT SAFETY INFORMATION
Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
*Subject to financial eligibility requirements. Other terms and restrictions apply.
If you have private insurance coverage, you may be eligible for the MyVTAMA Savings Program.
‡Income levels are subject to change on an annual basis; the numbers listed are based on the 2023 Federal Poverty Level Guidelines.
Not actual patients
Our goal at Dermavant is to bring treatment solutions to millions of patients suffering from chronic skin conditions through a best-in-class experience. Dermavant RxAssist is a program developed to help eligible patients gain access to our medication at no cost.*
Digital authorization to be enrolled in the program.
Real-time application submittal to speed up the process.
Upload supporting documentation with your application.
Your annual household income does not exceed 250% of the Federal poverty level‡:
Apply today to get your medication at no cost and start your therapy journey.
Our support teams are available to help you Monday through Friday, 8 a.m. – 5 p.m. ET.
IMPORTANT SAFETY INFORMATION
Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
*Subject to financial eligibility requirements. Other terms and restrictions apply.
†If you have private insurance coverage, you may be eligible for the MyVTAMA Savings Program.
‡Income levels are subject to change on an annual basis; the numbers listed are based on the 2023 Federal Poverty Level Guidelines.